ClinicalTrials.gg
CompletedNCT02611817Updated May 25, 2022Results posted

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

A Phase 3 interventional study of Vedolizumab SC 108 mg and Placebo in Crohn's Disease, sponsored by Takeda. Completed at 194 sites in 30 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
4th of 39
644 · median 101
Started
2016
with 6 others
Phase 3
16 of 39
6 open now
Registered
10th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 7 that started in 2016, is one of 16 in phase 3, and was the 10th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active CD who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.

Read the detailed description

The drug being tested in this study is called vedolizumab SC. Vedolizumab SC is being tested to treat people who have moderate to severely active CD. This study will look at clinical remission, as well as enhanced clinical response and corticosteroid-free remission in participants with CD who receive vedolizumab SC maintenance therapy after having achieved a clinical response to vedolizumab IV induction therapy.

The study will enroll approximately 824 participants. All participants will enter a 6 week Induction Phase where they will be administered open-label vedolizumab IV 300 mg via IV infusion at Week 0 (Day 1) and Week 2 (Day 15), and will then be assessed for a clinical response at Week 6. Participants who achieve a clinical response at Week 6 will be randomly assigned to one of the two treatment groups:

  • Vedolizumab SC 108 mg Maintenance Arm
  • Placebo SC Maintenance Arm

Participants who do not achieve a clinical response will not be randomized into the Maintenance Period, and instead will receive a third infusion of vedolizumab IV 300 mg at Week 6.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 71 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of CD established at least 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report.
  2. Moderately to severely active CD as determined by a CDAI score of 220 to 450 and 1 of the following:

    • C-reactive protein (CRP) level greater than (>) 2.87 milligram per liter (mg/L) OR
    • Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each >0.5 centimeter [cm] in diameter) or 10 aphthous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD OR
    • Fecal calprotectin >250 microgram per gram (mcg/g) stool during the screening period in conjunction with computed tomography enterography (CTE), magnetic resonance enterography (MRE), contrast-enhanced small bowel radiography, or wireless capsule endoscopy revealing CD ulcerations (aphthae not sufficient).
  3. CD involvement of the ileum and/or colon, at a minimum.
  4. Inadequate response with, loss of response to, or intolerance to , immunomodulators, or Tumor necrosis factor-alpha (TNF-α) antagonists.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of abdominal abscess at Screening.
  2. Extensive colonic resection, subtotal or total colectomy.
  3. History of >3 small bowel resections or diagnosis of short bowel syndrome.
  4. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  5. Prior exposure to or approved non-biologic therapies (example, cyclosporine, tacrolimus, thalidomide, or tofacitinib) for the treatment of underlying disease within 30 days or 5 half-lives of screening (whichever is longer).
  6. Prior exposure to any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of screening (whichever is longer).
  7. Prior exposure to vedolizumab.
  8. Surgical intervention for CD required at any time during the study.
  9. History or evidence of adenomatous colonic polyps that have not been removed, or of colonic mucosal dysplasia.
  10. Suspected or confirmed diagnosis of ulcerative colitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.
  11. Active infections.
  12. Chronic virus (HBV) or C () infection, tuberculosis (TB) (active or latent), or congenital or acquired immunodeficiency. HBV immune participants (that is, being hepatitis B surface antigen [HBsAg] negative and hepatitis B antibody positive) may, however, be included.
  13. History of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
644 participants (actual)

Study arms

  • Experimental
    Vedolizumab SC 108 mg Maintenance Arm

    Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50

    Drug: Vedolizumab SC 108 mg · Drug: Vedolizumab IV 300 mg

  • Placebo comparator
    Placebo SC Maintenance Arm

    Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50

    Drug: Placebo · Drug: Vedolizumab IV 300 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission at Week 52

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than or equal to (\<=) 150 at Week 52. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to (=) sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Enhanced Clinical Response at Week 52

    Enhanced clinical response is defined as a decrease from Baseline of greater than or equal to (\>=) 100 points in the CDAI score at Week 52. A CDAI is a multi-item instrument which measures severity of active CD monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: Week 52

  2. Percentage of Participants Achieving Corticosteroid-free Remission at Week 52

    Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: Week 52

  3. Percentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 52

    Clinical remission is defined as CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

    Time frame: Week 52

07

Results

Posted Jun 23, 2020

Participant flow

Participants with moderate to severe Crohn's disease (CD) took part in the study at 169 investigative sites in North America, South America, Western/Northern Europe, Central Europe, Eastern Europe, East Asia, and Africa/Australia from 04 Jan 2016 to 06 Aug 2019.

Open-label Induction Phase
Participant flow — Open-label Induction Phase
MilestoneOpen-label Induction Phase: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Started64400
Completed59400
Not completed5000
Withdrew: Reason not specified900
Withdrew: Lack of efficacy800
Withdrew: Pregnancy100
Withdrew: Withdrawal by subject900
Withdrew: Lost to follow-up200
Withdrew: Protocol violation500
Withdrew: Adverse event1600
Double-blind Maintenance Phase
Participant flow — Double-blind Maintenance Phase
MilestoneOpen-label Induction Phase: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Started0135275
Completed073168
Not completed062107
Withdrew: Adverse event01211
Withdrew: Randomized but not treated010
Withdrew: Reason not specified012
Withdrew: Lack of efficacy04378
Withdrew: Pregnancy001
Withdrew: Withdrawal by subject0514
Withdrew: Lost to follow-up001

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission at Week 52

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than or equal to (\<=) 150 at Week 52. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to (=) sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Percentage of Participants Achieving Clinical Remission at Week 5234.3 (26.3 to 43.0)48.0 (42.0 to 54.1)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = 0.008 · Clopper-pearson method: 13.7 · 95% CI 3.8 to 23.7
SecondaryPercentage of Participants Achieving Enhanced Clinical Response at Week 52

Enhanced clinical response is defined as a decrease from Baseline of greater than or equal to (\>=) 100 points in the CDAI score at Week 52. A CDAI is a multi-item instrument which measures severity of active CD monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Enhanced Clinical Response at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Percentage of Participants Achieving Enhanced Clinical Response at Week 5244.8 (36.2 to 53.6)52.0 (45.9 to 58.0)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = 0.167 · Clopper-pearson method: 7.3 · 95% CI -3.0 to 17.5
SecondaryPercentage of Participants Achieving Corticosteroid-free Remission at Week 52

Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Corticosteroid-free Remission at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Percentage of Participants Achieving Corticosteroid-free Remission at Week 5218.2 (8.2 to 32.7)45.3 (35.0 to 55.8)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = 0.002 · Clopper-pearson method: 27.1 · 95% CI 11.9 to 42.3
SecondaryPercentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 52

Clinical remission is defined as CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Percentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 5242.9 (30.5 to 56.0)48.6 (38.8 to 58.5)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = 0.591 · Clopper-pearson method: 4.3 · 95% CI -11.6 to 20.3

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to 18 weeks after the last dose of study drug (up to Week 68). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Phase Only: Vedolizumab 300 mg IV0/235 (0%)39/235 (16.6%)40/235 (17%)
Maintenance Phase: Induction IV + Placebo0/134 (0%)14/134 (10.4%)54/134 (40.3%)
Maintenance Phase: Induction IV + Vedolizumab 108 mg SC0/275 (0%)23/275 (8.4%)102/275 (37.1%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventInduction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Crohn's diseaseGastrointestinal disorders14/2355/1346/275
Abdominal abscessInfections and infestations4/2350/1340/275
Small intestinal obstructionGastrointestinal disorders1/2352/1341/275
Anal abscessInfections and infestations2/2351/1341/275
Abdominal painGastrointestinal disorders2/2350/1340/275
AnaemiasBlood and lymphatic system disorders1/2351/1341/275
LeukocytosisBlood and lymphatic system disorders0/2351/1340/275
PancreatitisGastrointestinal disorders0/2351/1340/275
Anal fistulaGastrointestinal disorders1/2351/1341/275
Enterovesical fistulaGastrointestinal disorders0/2351/1340/275
Most frequent other events
Most frequent other events
EventInduction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SC
Crohn's diseaseGastrointestinal disorders7/23523/13436/275
NasopharyngitisInfections and infestations7/2356/13425/275
Abdominal painGastrointestinal disorders9/23511/13421/275
ArthralgiaMusculoskeletal and connective tissue disorders8/2359/13417/275
Upper respiratory tract infectionInfections and infestations2/2355/13417/275
HeadacheNervous system disorders10/2355/13415/275
NauseaGastrointestinal disorders9/2357/13411/275
VomitingGastrointestinal disorders4/2357/1346/275

Baseline characteristics

The safety analysis set-combined (SAF-C) included all participants who received at least 1 dose of study vedolizumab IV.

Age, Continuous
Age, Continuous(years)Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
Mean37.4 ± 12.7936.1 ± 12.9338.2 ± 13.8537.5 ± 13.29
Sex: Female, Male
Sex: Female, Male(Participants)Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
Female11968118305
Male11666157339
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
Hispanic or Latino0123
Not Hispanic or Latino502060130
Unknown or Not Reported185113213511
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
American Indian or Alaska Native0202
Asian2361746
Native Hawaiian or Other Pacific Islander2103
Black or African American31711
White207124250581
More than one race0011
Unknown or Not Reported0000
Weight
Weight(kilogram (kg))Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
Mean69.94 ± 18.40369.79 ± 18.10374.08 ± 18.99471.68 ± 18.684
Body Mass Index
Body Mass Index(kilogram per square meter (kg/m^2))Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
Mean24.20 ± 6.07323.93 ± 5.54125.06 ± 5.91524.51 ± 5.909
Smoking Classification
Smoking Classification(Participants)Induction Phase Only: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCTotal
Never smoked14085148373
Current smoker492654129
Ex-smoker462373142
08

Study locations

194 sites
  • Arizona Arthritis & Rheumatology Research, PLLC
    Phoenix, Arizona 45806, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 11021, United States
  • Middlesex Gastroenterology Associates
    Middletown, Connecticut, United States
  • Nature Coast Clinical Research, LLC
    Inverness, Florida 55905, United States
  • L & L Research Choices, Inc.
    Miami, Florida, United States
  • Gastroenterology Group of Naples
    Naples, Florida 30342, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 70809, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 33176, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 53226, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 48047, United States
  • Grand Teton Research Group, PLL
    Idaho Falls, Idaho, United States
  • Rush University Medical Center
    Chicago, Illinois 33028, United States
  • Carle Foundation Hospital
    Urbana, Illinois 74104, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 06518, United States
  • Tri-State Gastroenterology Associates
    Crestview Hills, Kentucky 06457, United States
  • Gastroenterology Associates, LLC
    Baton Rouge, Louisiana 85307, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 32789, United States
  • Metropolitan Gastroenterology Group, PC, Chevy Chase Clinical Research
    Chevy Chase, Maryland, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 49519, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 34102, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 30024, United States
  • Ehrhardt Clinical Research, LLC
    Belton, Missouri 60612, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 71105, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 41017, United States
  • Gastro-Enterology Research of Lima
    Lima, Ohio 39581, United States
  • Options Health Research
    Tulsa, Oklahoma 83404, United States
  • Gastroenterology Center of the MidSouth PC
    Germantown, Tennessee 78212, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 61801, United States
  • San Antonio Gastroenterology
    San Antonio, Texas, United States
  • Allegiance Research Specialists, LLC
    Milwaukee, Wisconsin 64012, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Tennyson Centre Day Hospital
    Bedford Park, South Australia 5042, Australia
  • Ballarat Base Hospital
    Ballarat, Victoria 3350, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3181, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • AZ Groeninge - Kennedylaan
    Kortrijk, 8500, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • University Clinical Hospital Mostar
    Mostar, 88000, Bosnia and Herzegovina
  • Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda
    Goiania, Goias 74535-170, Brazil
  • HUGG - Hospital Universitario Gaffree e Guinle
    Rio de Janeiro, Rio Do Janeiro 20270-004, Brazil
  • HUCFF-UFRJ - Hospital Universitario Clementino Fraga Filho - Universidade Federal do Rio de Janeiro
    Rio de Janeiro, Rio Do Janeiro 21941-913, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, Sao Paulo 18618-970, Brazil
  • Faculdade de Medicina do ABC
    Santo Andre, Sao Paulo 09060-650, Brazil
  • Irmandade da Santa Casa da Misericordia de Santos
    Santos, Sao Paulo 11075-900, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • "City Clinic UMHAC" EOOD
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • UMHAT 'Tsaritsa Yoanna - ISUL', EAD
    Sofia, 1527, Bulgaria
  • Fourth MHAT - Sofia EAD
    Sofia, 1606, Bulgaria
  • Zeidler Ledcor Centre - University of Alberta
    Edmonton, Alberta T6G 2X8, Canada
  • PerCuro Clinical Research Ltd.
    Victoria, British Columbia V8V 3M9, Canada
  • LHSC - University Hospital
    London, Ontario N6A 5A5, Canada
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Toronto Digestive Disease Associates, Inc.
    Vaughan, Ontario L4L 4Y7, Canada
  • CCBR - Czech Brno, s.r.o..
    Brno, 60200, Czechia
  • Hepato-Gastroenterologie HK s.r.o.
    Hradec Kralove, 500 12, Czechia
  • A-SHINE s.r.o.
    Plzen, 31200, Czechia
  • CCBR Czech Prague, s.r.o.
    Praha 3, 13000, Czechia
  • Axon Clinical s.r.o.
    Praha 5, 15000, Czechia
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Regionshospitalet Silkeborg
    Silkeborg, 8600, Denmark
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, Rheinland Pfalz 55131, Germany
  • EUGASTRO GmbH
    Leipzig, Sachsen 04103, Germany
  • DRK Kliniken Berlin Westend
    Berlin, 14050, Germany
  • Krankenhaus Waldfriede e. V.
    Berlin, 14163, Germany
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 1036, Hungary
  • Semmelweis Egyetem
    Budapest, 1088, Hungary
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
    Budapest, 1125, Hungary
  • Pannonia Maganorvosi Centrum
    Budapest, 1136, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz
    Miskolc, 3526, Hungary
  • Karolina Korhaz-Rendelointezet
    Mosonmagyarovar, H-9200, Hungary
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
    Szekesfehervar, 8000, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszard, 7100, Hungary
  • HaEmek Medical Center
    Afula, 18101, Israel
  • Soroka University Medical Center
    Beer Sheva, 8410101, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Kaplan Medical Center
    Rechovot, 7610001, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Foggia 71013, Italy
  • I.R.C.C.S Policlinico San Donato
    San Donato Milanese (MI), Milano 20097, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliera Ospedale Cannizzaro
    Catania, 95100, Italy
  • Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco)
    Milano, 20157, Italy
  • A.O.U. Policlinico di Modena
    Modena, 41124, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera Vincenzo Cervello
    Palermo, 90146, Italy

Showing the first 100 of 194 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in May 2019, 40 months.

Results were first posted in Jun 2020, 1 year 1 month after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 40 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2015
First posted
Nov 23, 2015
StartActual
Jan 4, 2016
Primary completionActual
May 6, 2019
CompletionActual
Aug 6, 2019
Results first posted
Jun 23, 2020
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02611817
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 23, 2015
Start date
Jan 4, 2016
Primary completion
May 6, 2019
Completion
Aug 6, 2019
Results posted
Jun 23, 2020
Last update
May 25, 2022

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion